Healthequity opened higher at $101.86, compared with its previous close of $101.36. In the last trading session, the stock traded between $100.90 and $103.00. It showed a sideways intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Healthequity is now worth
$ 153.63
giving a profit of
$ 53.63 (53.63%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 9 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.32 (+0.31%)
Day High
$103.00
Day Low
$100.90
Day Open
$101.86
Prev Close
$101.36
Volume
1,88,678
1W Return
0.67%
1M Return
16.61%
3M Return
-2.27%
6M Return
24.79%
1Y Return
7.66%
Fundamentals
Market Cap ($ Mn)
8,410
PE Ratio
34.79
PB Ratio
4.01
PEG Ratio
0.17
ROE
10.13%
ROCE
9.85%
EPS (TTM)
$0.79
Investment Returns
1 Week
0.67%
1 Month
16.61%
3 Months
-2.27%
6 Months
24.79%
9 Months
21.66%
Financials
Quarterly
All values in $ Mn
330.8
Apr 25
325.8
Jul 25
322.2
Oct 25
334.6
Jan 26
354.6
Apr 26
350.7
Jul 26
Updates
21Oct
BMO raises HealthEquity price target to $125, maintains Outperform
BMO Capital raised the price target for HealthEquity to $125. The previous price target was set at $105. Analyst Sean Dodge maintained an Outperform rating on the stock.
8 days ago
18Sep
Barclays raises HealthEquity price target to $115, maintains Overweight
Barclays raises HealthEquity price target to $115 from $110. Peter Warendorf maintains Overweight rating on HQY stock. The $5 increase reflects refined valuation assumptions. Analyst retains bullish stance on the healthcare tech firm.
1mo ago
28Aug
BTIG reiterates Buy on HealthEquity, maintains $115 price target
BTIG analyst David Larsen reiterates a Buy rating on HealthEquity. The firm maintains a $115 price target for the stock. No changes were made to the previous valuation or recommendation.
2mo ago
27Aug
HealthEquity Q2FY27 Results: Revenue up 8%, record $65.6M net income
Revenue grew 8% YoY with service revenue hitting a record $124.4 million. Adjusted EBITDA margin expanded to a record 48%, up from 46% last year. GAAP net income reached $65.6 million; non-GAAP net income was $103.8 million. Full-year fiscal 2027 guidance raised across revenue, earnings, and EBITDA metrics. HSA accounts hit a record 10.7 million, with assets up 14% year over year.
2mo ago
27Aug
HealthEquity raises FY27 sales and GAAP EPS guidance vs estimates
HealthEquity raises FY27 GAAP EPS guidance top-end to $2.96 from $2.95. New GAAP EPS range of $2.88-$2.96 beats $2.94 analyst estimate. FY27 sales guidance lifted to $1.411B-$1.421B from $1.410B-$1.420B. Adjusted EPS guidance remains unchanged at $4.66-$4.73.
2mo ago
27Aug
HealthEquity Q2 Results: EPS beats estimate, revenue up 7.6%
Adjusted EPS of $1.24 beat the $1.19 estimate by 4.2%. Revenue rose 7.64% YoY to $350.732 million. Sales surpassed the $349.248 million consensus estimate. EPS growth of 14.81% outpaced revenue growth.
